NEW YORK, April 4, 2014 /PRNewswire/ --
Today, Analysts Review released its analysts' notes regarding
Arrowhead Research Corp. (NASDAQ: ARWR), Providence Service Corp.
(NASDAQ: PRSC), Durata Therapeutics, Inc. (NASDAQ: DRTX), Orthofix
International N.V. (NASDAQ: OFIX), and Idera Pharmaceuticals, Inc.
(NASDAQ: IDRA). Private wealth members receive these notes ahead of
publication. To reserve complementary membership, limited openings
are available at: http://www.AnalystsReview.com/register
--
Arrowhead Research Corp. Analyst Notes
On April 1, 2014, Arrowhead
Research Corp. (Arrowhead) announced that it has successfully
completed enrollment of 8 patients in a Phase 2a clinical trial of
ARC-520, its RNAi therapeutic for the treatment of chronic
hepatitis B virus (HBV) infection. "The pace of patient accrual for
the ARC-520 Phase 2a study has been very encouraging with the first
dose group being enrolled and dosed in just over a week," said
Christopher Anzalone, Ph.D.,
Arrowhead's President and CEO. "According to the study protocol, we
expect to begin dosing the next cohort in May and remain confident
that we can release top line data in the third quarter. ARC-520 has
the potential to be the first drug candidate ever to demonstrate
consistent hepatitis B surface antigen reduction in humans, which
is thought to be critical in achieving a functional cure for
chronic HBV." The full analyst notes on Arrowhead Research Corp.
are available to download free of charge at:
http://www.AnalystsReview.com/04042014/ARWR/report.pdf
--
Providence Service Corp. Analyst Notes
On March 31, 2014, Providence
Service Corp. (Providence)
announced that it has entered into an agreement to acquire Ingeus
Limited (Ingeus). According to the Company, under the terms of the
agreement, Providence will acquire
100% of Ingeus for £35 million or $58
million in cash. Providence's CEO, Warren Rustand commented, "Ingeus complements
our existing businesses, both strategically and culturally, and
shares our core values, focus on integrity, and commitment to
customer-centered care through innovation. Importantly, because
there is no overlap of current clients, there will be significant
opportunity for sharing of expertise." The full analyst notes on
Providence Service Corp. are available to download free of charge
at:
http://www.AnalystsReview.com/04042014/PRSC/report.pdf
--
Durata Therapeutics, Inc. Analyst Notes
On March 31, 2014, Durata
Therapeutics Inc. (Durata) announced that the U.S. Food and Drug
Administration's Anti-Infective Drugs Advisory Committee voted 12
to 0 that the Company has provided substantial evidence of the
safety and effectiveness of its investigational drug,
Dalvance[TM] (dalbavancin) for
injection. According to the Company,
Dalvance[TM] for injection is
meant for the treatment of adult patients with acute bacterial skin
and skin structure infections, caused by susceptible Gram-positive
bacteria, including methicillin-resistant Staphylococcus aureus.
Paul R. Edick, Durata's CEO
commented, "We are pleased with the positive outcome of today's
Advisory Committee meeting, and the confidence that was expressed
regarding the safety and effectiveness of Dalvance. If approved by
the FDA, Dalvance would be the first once-weekly antibiotic for
ABSSSI, providing an alternative to current once- or twice-daily
treatments." The full analyst notes on Durata Therapeutics, Inc.
are available to download free of charge at:
http://www.AnalystsReview.com/04042014/DRTX/report.pdf
--
Orthofix International N.V. Analyst Notes
On March 27, 2014, Orthofix
International N.V. (Orthofix) reported its Q4 2013 and full-year
2013 financial results. For the quarter, net sales were
$106.1 million, down 9.6% YoY. Net
loss from continuing operations was $9.3
million in Q4 2013, compared to a net income of $16.0 million in Q4 2012. For full year 2013, net
sales totaled $400.5 million, down
10.5% YoY. Net loss from continuing operations was $15.7 million in full year 2013, compared to a
net income of $45.1 million in full
year 2012. Orthofix's President and CEO, Brad Mason commented, "This past year has been
challenging and the 2013 financial performance is not reflective of
where the Company should be operating. However, we expect stronger
financial results in 2014 and are laying the groundwork for further
growth and profitability in 2015 and 2016. We are confident that
the changes we have made and the initiatives currently underway are
resulting in a stronger Company driven by integrity and with a
renewed focus on delivering results that meet or exceed our
stakeholders' expectations." The full analyst notes on Orthofix
International N.V. are available to download free of charge at:
http://www.AnalystsReview.com/04042014/OFIX/report.pdf
--
Idera Pharmaceuticals, Inc. Analyst Notes
On March 28, 2014, Idera
Pharmaceuticals, Inc. (Idera) announced positive top-line data from
its randomized, double-blind, placebo controlled Phase 2 trial of
IMO-8400 in 32 patients with moderate-to-severe plaque psoriasis.
The Company informed that the trial met its primary objective to
evaluate the safety and tolerability of IMO-8400 over a 12-week
treatment period, as well as its secondary objective of
demonstrating clinical activity in patients with psoriasis as
assessed by Psoriasis Area and Severity Index (PASI). Sudhir Agrawal, D. Phil., CEO of Idera,
commented. "With these data, we can now pursue our announced
business strategy and advance our TLR antagonist drug candidates
for the treatment of orphan diseases with high unmet medical need.
Towards this goal, our clinical development strategy for IMO-8400
is focused on B-cell lymphomas harboring the MYD88 L265P mutation,
and on orphan autoimmune disease indications." The full analyst
notes on Idera Pharmaceuticals, Inc. are available to download free
of charge at:
http://www.AnalystsReview.com/04042014/IDRA/report.pdf
--
About Analysts Review
We provide our members with a simple and reliable way to leverage
our economy of scale. Most investors do not have time to track all
publicly traded companies, much less perform an in-depth review and
analysis of the complexities contained in each situation. That's
where Analysts Review comes in. We provide a single unified
platform for investors' to hear about what matters. Situation
alerts, moving events, and upcoming opportunities.
--
=============
EDITOR NOTES:
- This is not company news. We are an independent source and our
views do not reflect the companies mentioned.
- Information in this release is fact checked and produced on a
best efforts basis and reviewed by Nidhi Vatsal, a CFA
charterholder. However, we are only human and are prone to make
mistakes. If you notice any errors or omissions, please notify us
below.
- This information is submitted as a net-positive to companies
mentioned, to increase awareness for mentioned companies to our
subscriber base and the investing public.
- If you wish to have your company covered in more detail by our
team, or wish to learn more about our services, please contact us
at pubco [at] AnalystsReview.com.
- For any urgent concerns or inquiries, please contact us
at compliance [at] AnalystsReview.com.
- Are you a public company? Would you like to see similar
coverage on your company? Send us a full investors' package to
research [at] AnalystsReview.com for consideration.
COMPLIANCE PROCEDURE
Content is researched, written and reviewed on a best-effort
basis. This document, article or report is prepared and authored by
Analysts Review. An outsourced research services provider
represented by Nidhi Vatsal, CFA, has only reviewed the information
provided by Analysts Review in this article or report according to
the Procedures outlined by Analysts Review. Analysts Review is not
entitled to veto or interfere in the application of such procedures
by the outsourced provider to the articles, documents or reports,
as the case may be.
NOT FINANCIAL ADVICE
Analysts Review makes no warranty, expressed or implied, as to
the accuracy or completeness or fitness for a purpose (investment
or otherwise), of the information provided in this document. This
information is not to be construed as personal financial advice.
Readers are encouraged to consult their personal financial advisor
before making any decisions to buy, sell or hold any securities
mentioned herein.
NO WARRANTY OR LIABILITY ASSUMED
Analysts Review is not responsible for any error which may be
occasioned at the time of printing of this document or any error,
mistake or shortcoming. No liability is accepted by Analysts Review
whatsoever for any direct, indirect or consequential loss arising
from the use of this document. Analysts Review expressly disclaims
any fiduciary responsibility or liability for any consequences,
financial or otherwise arising from any reliance placed on the
information in this document. Analysts Review does not (1)
guarantee the accuracy, timeliness, completeness or correct
sequencing of the information, or (2) warrant any results from use
of the information. The included information is subject to change
without notice.
CFA® and Chartered Financial Analyst® are registered trademarks
owned by CFA Institute.
AnalystsReview.com
SOURCE Analysts Review